July 2026
- Breaking the RAS Barrier in Pancreatic Cancer
- Daraxonrasib in Advanced RAS-Mutated Pancreatic Cancer
- Klebsiella Brain Abscess and Evolution of Heterovirulence in the Urinary Tract
- More on Digital Twin–Guided Ablation for Ventricular Tachycardia
- Left Atrial Appendage Closure in Atrial Fibrillation
- Antiretroviral Therapy
- Koebner Phenomenon from Wet Cupping
- Case 21-2026: A 28-Year-Old Man with Headache and Vision Loss in the Right Eye
- A New Standard in Muscle-Invasive Bladder Cancer — The End of the Cisplatin Era?
- Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
- Crew Resource Management — Navigating AI’s Automation Paradox
- Cross-Reactive Bundibugyo Antibody Responses after Receipt of Licensed Ebola Vaccines
- Cardiotoxic Effects and Microdystrophin Expression after Gene Therapy for DMD
- The Best of Both Worlds — Using Clinical Trial and Observational Data to Evaluate Vaccine Protection
- When Celebrities Prescribe — Regulating Drug Promotion on the Internet
- Love and Death
- National Elimination of Hepatitis C — The Case for Starting in Prisons and Jails
- Neurocysticercosis
- A Regional Measles Outbreak — South Carolina, 2025–2026
- Andes Virus — A Clinical Review
- Platelet-Activating Anti–Platelet Factor 4 Disorders
- Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty
- Long-Term Survival of Hypoimmune Allogeneic Islets without Immunosuppression
- Meningococcal B Vaccine to Prevent Neisseria gonorrhoeae Infection
- Ebola at 50 — Lessons for Outbreak Response and Preparedness
- Retraction: Jayne DRW et al. Avacopan for the Treatment of ANCA-Associated Vasculitis, N Engl J Med 2021;384:599-609.
- Phase 3 Trial of Oral Infigratinib in Children with Achondroplasia
- Long-Acting Treatment and Advanced HIV Disease — Addressing a Public Health Priority
- Clinical Characteristics of Patients Infected with Bundibugyo Virus, DRC 2026
- The Social Contract of Bundibugyo Ebola Isolation
- Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?
- Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
- Clinical Long-Read Genome Sequencing for Rare-Disease Diagnostics
- Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema
- Sodium Bicarbonate for Critically Ill Adults with Metabolic Acidosis and Shock
- Vasopressors or Fluids in Early Septic Shock
- Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease
- Carbocisteine or Hypertonic Saline for Acute Respiratory Failure
- Conservative Oxygen for Unresponsive Patients after Cardiac Arrest
- Survodutide Once Weekly for the Treatment of Adults with Obesity
- Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy
- Finerenone in Persons with Chronic Kidney Disease without Diabetes
- Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica
- Emerging Era for Polymyalgia Rheumatica and GCA — Interleukin-17A Targeting
- Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease
- Obexelimab for the Treatment of IgG4-Related Disease
- Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
- A Watershed Moment in the Perioperative Treatment of Prostate Cancer
- Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer
- Perioperative Apalutamide in High-Risk Localized Prostate Cancer